- Home
- CVBF vs RYTM Comparison
CVBF vs RYTM Comparison
Compare CVBF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVBF
- RYTM
- Stock Information
- Founded
- CVBF 1974
- RYTM 2008
- Country
- CVBF United States
- RYTM United States
- Employees
- CVBF N/A
- RYTM N/A
- Industry
- CVBF Major Banks
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- CVBF Finance
- RYTM Health Care
- Exchange
- CVBF Nasdaq
- RYTM Nasdaq
- Market Cap
- CVBF 2.7B
- RYTM 4.3B
- IPO Year
- CVBF N/A
- RYTM 2017
- Fundamental
- Price
- CVBF $21.00
- RYTM $82.64
- Analyst Decision
- CVBF Buy
- RYTM Strong Buy
- Analyst Count
- CVBF 4
- RYTM 13
- Target Price
- CVBF $23.50
- RYTM $78.31
- AVG Volume (30 Days)
- CVBF 806.3K
- RYTM 617.4K
- Earning Date
- CVBF 07-23-2025
- RYTM 08-05-2025
- Dividend Yield
- CVBF 3.82%
- RYTM N/A
- EPS Growth
- CVBF N/A
- RYTM N/A
- EPS
- CVBF 1.45
- RYTM N/A
- Revenue
- CVBF $506,920,000.00
- RYTM $136,863,000.00
- Revenue This Year
- CVBF N/A
- RYTM $37.56
- Revenue Next Year
- CVBF $5.98
- RYTM $74.99
- P/E Ratio
- CVBF $14.44
- RYTM N/A
- Revenue Growth
- CVBF N/A
- RYTM 48.88
- 52 Week Low
- CVBF $16.01
- RYTM $40.61
- 52 Week High
- CVBF $24.58
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- CVBF 71.31
- RYTM 77.65
- Support Level
- CVBF $20.53
- RYTM $64.65
- Resistance Level
- CVBF $21.09
- RYTM $67.75
- Average True Range (ATR)
- CVBF 0.46
- RYTM 2.46
- MACD
- CVBF 0.20
- RYTM 1.20
- Stochastic Oscillator
- CVBF 96.89
- RYTM 90.57
About CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.